In-Depth Study on Streptococcal Pneumonia - Pipeline Review, H2 2016
Streptococcal Pneumonia - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Streptococcal Pneumonia (Infectious Disease) pipeline landscape.
Pneumococcal infections are caused by the Streptococcus pneumoniae (S. pneumoniae) bacterium. They can be mild or severe. Symptoms include fever, chills, sweat, aches and pains. Risk factors include serious health condition, such as HIV or diabetes that weakens their immune system, taking medication that weakens their immune system, such as chemotherapy and age. Treatment includes antibiotics.
Complete report available @ Streptococcal Pneumonia - Pipeline Review, H2 2016
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Streptococcal Pneumonia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Streptococcal Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Streptococcal Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Streptococcal Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 6, 6, 2, 22, 10 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 1, 8 and 4 molecules, respectively.
Streptococcal Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Streptococcal Pneumonia (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Streptococcal Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Streptococcal Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Streptococcal Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Streptococcal Pneumonia (Infectious Disease)
- The pipeline guide reviews pipeline therapeutics for Streptococcal Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Streptococcal Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Streptococcal Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Streptococcal Pneumonia (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Streptococcal Pneumonia (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Streptococcal Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Streptococcal Pneumonia (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Streptococcal Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Abera Bioscience AB Actelion Ltd Affinivax Inc Allergan Plc Arsanis Inc AstraZeneca Plc Beijing Minhai Biotechnology Co Ltd Biken Inc ContraFect Corp Crestone Inc Daiichi Sankyo Company Ltd FluGen Inc GlaxoSmithKline Plc ImmunoBiology Ltd Indian Immunologicals Ltd Integrated BioTherapeutics Inc Lascco SA LegoChem Biosciences Inc Liquidia Technologies Inc Merck & Co Inc Mucosis BV Panacea Biotec Ltd Pfizer Inc Prometheon Pharma LLC Sanofi Pasteur SA Serum Institute of India Ltd Shionogi & Co Ltd SK Chemicals Co Ltd Sumitomo Dainippon Pharma Co Ltd Valneva SE Vaxxilon AG Virometix AG Wellstat Vaccines LLC Wockhardt Ltd
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
posted by Reportstack @ 04:42
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home